biphasic insulin aspart 50 + biphasic insulin aspart 30 + metformin

This drug is a combination therapy consisting of **biphasic insulin aspart 50**, **biphasic insulin aspart 30**, and **metformin**. Biphasic insulin aspart 30 and 50 are premixed formulations of the rapid-acting insulin analog aspart with protamine, providing both immediate and intermediate insulin effects. **Metformin** is an oral antihyperglycemic agent in the biguanide class. This combination is used in the management of type 2 diabetes mellitus and aims to improve glycaemic control by combining distinct mechanisms: insulin aspart directly lowers blood glucose by facilitating cellular uptake, while metformin reduces hepatic glucose production and increases peripheral insulin sensitivity. The combination has demonstrated improved glycemic control without substantial increase in hypoglycemia risk when compared to insulin regimens alone[1][2][3][4][5].